MedTrace Logo

Efficacy and Safety of LongShengZhi Capsule on Functional Recovery After Acute Ischaemic Stroke (LONGAN)

NCT05277311 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1376

Last updated 2022-03-14

No results posted yet for this study

Summary

The aim of the study is to determine if LongShengZhi Capsule is effective and safe in patients with ischemic stroke in comparison to placebo. This trial is a prospective, multicenter, randomized, placebo-controlled, double-blinded, parallel-group, superiority trial.

Conditions

Interventions

DRUG

LongShengZhi capsule

LongShengZhi capsules, orally, 5 capsules each time, three times a day.

DRUG

LongShengZhi capsule placebo

LongShengZhi capsules placebo, orally, 5 capsules each time, three times a day.

Sponsors & Collaborators

  • Dongzhimen Hospital, Beijing

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-12-31
Completion
2024-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05277311 on ClinicalTrials.gov